π¬ New antibody drug cuts inflammation markers
The monoclonal antibody, pacibekitug, showed sustained reductions in inflammatory markers during the TRANQUILITY trial. This study took place in Munich, Germany, involving patients with chronic kidney disease. The trial included 143 patients over six months, showing significant decreases in hs-CRP. Inflammation is now seen as a key driver of cardiovascular disease, which this drug targets. Researchers plan a larger phase III trial to see if these effects improve patient cardiovascular outcomes. π©Ί